Skip to main content
Clinical Trials/NCT02567929
NCT02567929CompletedNot Applicable

Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer

Konkuk University Medical Center1 site in 1 country218 target enrollmentStarted: March 2016Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
218
Locations
1
Primary Endpoint
CD39 and CD73 on circulating regualtory T cells

Study Overview

Brief Summary

Anesthetics agents has variety inflammation during the cancer surgery. This perioperative inflammation can influence to cancer metastasis or recurrence.

The purpose of this study is to prove the variation of immune cell activity between preoperative and postoperative period.

Detailed Description

The patients were allocated randomly to receive propofol or sevoflurane. Also, a total of 18ml of blood sample was obtained for total 3 times in consecutive order.

  1. immediate before anesthesia induction
  2. postoperative 1 hours
  3. postoperative 24 hours

Serum in blood will be obtained and activity of helper T cell, natural killer cell and level of serum cytokine will be evaluated by flow cytometry or enzyme-linked immunosorbent assay

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Factorial
Primary Purpose
Basic Science
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
20 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • patient who was planned to undergo colon cancer surgery.

Exclusion Criteria

  • age < 20 years old
  • history of hypersensitivity reaction in propofol or sevoflurane
  • history of previous cancer
  • patient with ongoing inflammation

Arms & Interventions

propofol group

Active Comparator

The patient who anesthetized by using propofol.

Intervention: propofol group (Drug)

sevoflurane group

Active Comparator

The patient who anesthetized by using propofol

Intervention: sevoflurane group (Drug)

Outcomes

Primary Outcomes

CD39 and CD73 on circulating regualtory T cells

Time Frame: preoperative time. postoperative 1 hours and 24 hours

change of percentage of CD39 and CD73 (scores range from 0 to 100)

Secondary Outcomes

  • Circulating natural killer cells(preoperative time. postoperative 1 hours and 24 hours)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Seong-Hyop Kim

Associate Professor

Konkuk University Medical Center

Study Sites (1)

Loading locations...

Similar Trials

Assessment of the Anesthetic Effect on the... | Clinical Trial